A phase II, prospective, randomized, double-blind, placebo, controlled trial to assess the safety and tolerability of influenza virus vaccine, trivalent, types A and B live cold-adapted liquid formulation (CAIV-T) [influenza virus vaccine live] in healthy children and adolescents ages 6 to less than 18 years
Latest Information Update: 16 Jan 2007
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 27 Dec 2006 Status change
- 12 Dec 2005 New trial record.